Scalper1 News
Chinese contract research organization WuXi PharmaTech (WX) beat Wall Street’s earnings estimates in its Q4 report and 2014 guidance, though revenue was in-line and its Q1 guidance missed expectations. The stock dropped more than 7% in after-hours trading. WuXi’s revenue in the quarter rose 25% vs. a year earlier to $157.2 million, slightly above analysts’ consensus, according to Thomson Reuters. That was the second straight quarter of Scalper1 News
Scalper1 News